Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GILEAD SCIENCES Latest News

MAR 21, 2014 - Los Angeles Times

A Must Read - Share

Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

Lawmakers ask Gilead CEO John C. Martin to explain the rationale for selling Sovaldi for $1,000 per pill, or $84,000 for a 12-week course to treat hepatitis C.U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers.    

Tags: Gilead Sciences' $84,000 price for hepatitis drug is scrutinized,  Gilead Sciences Latest News